Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide

Blood

Volumn 89, Issue 6, 1997, Pages 2203-2209

  Hess, Allan D ^a   Bright, Emilie C ^a   Thoburn, Christopher ^a   Vogelsang, Georgia B ^a   Jones, Richard J ^a   Kennedy, M John ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYCLOSPORIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; THIOTEPA;

ADULT; ANTIGEN RECOGNITION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CELL ISOLATION; CELL MEDIATED LYMPHOLYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0030892020     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.2203     Document Type: Article

References (33)

1. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Schlossman SF, Nadler LM, Mauch P, Tarbell N, Coral F, Daley H, Yeap B: Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 316:1499, 1987
2. Jones RJ, Piatadosi S, Mann RB, Ambinder RF, Siefter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD, Vogelsang GB, Wagner JE, Wiley JM, Wingard JR, Yeager AM, Saral R: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527, 1990
3. Bezusda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483, 1995
4. Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991
5. Fuchs EJ, Bedi A, Jones RJ, Hess AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 55:463, 1995
6. Hess AD: Syngeneic/autologous graft-vs-host disease: Mobilization of autoimmune mechanisms as antitumor immunotherapy. Cancer Control 1:201, 1994
7. Hess AD: Autologous graft-versus-host disease: A novel approach for antitumor immunotherapy. Hum Immunol 34:219, 1992
8. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW: Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1:754, 1989
9. Hess AD, Horwitz LR, Beschorner WE, Santos GW: Development of GVHD-like syndrome in CsA-treated rats after syngeneic BMT. J Exp Med 161:718, 1985
10. Jenkins MK, Schwartz RH, Pardoll DM: Effects of cyclosporine A on T cell development and clonal deletion. Science 241:1655, 1988
11. Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD: Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74:1165, 1989
12. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD: Interferon-γ potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1:75, 1992
13. Jones RJ, Kennedy MJ, Hess AD: Autologous graft-vs-host disease. Bone Marrow Transpant 15:S119, 1995 (suppl 1)
14. Kennedy MJ, Vogensang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478, 1993
15. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD, Santos GW: Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 79:3031, 1992
16. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of interferon-gamma to potentiate cyclosporine A-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249, 1994
17. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920, 1991
18. Ruvolo PP, Bright EC, Kennedy MJ, Morris LE, Fischer AC, Vogelsang GB, Jones RJ, Hess AD: Cyclosporine-induced autologous graft-versus-host disease: Assessment of cytolytic effector mechanisms and the Vβ T cell receptor repertoire. Transplant Proc 27:1363, 1995
19. Woodland DL, Blackman MA: How do T-cell receptors, MHC molecules and superantigens get together? Immunol Today 14:208, 1993
20. Malcherek G, Gnau V, Jung G, Rammensee HG, Melms A: Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex class II molecules. J Exp Med 181:527, 1995
21. Freisewinkel IM, Schench K, Koch N: The segment of the invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 90:9703, 1993
22. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27, 1993
23. Ericson ML, Sundstrom M, Sansom DM, Charron DJ: Mutually exclusive binding of peptide and invariant chain to major histocompatibility complex class II antigens. J Biol Chem 269:26531, 1994
24. Hess AD, Thoburn C, Horwitz L, Bright E: Specificity of effector mechanisms in syngeneic graft-vs-host disease: Recognition of the MHC class II invariant chain peptide. Transpant Proc (in press)
25. Fischer AC, Ruvolo, PP, Burt R, Horwitz LR, Bright EC, Hess JM, Beschorner WE, Hess AD: Characterization of the autoreactive T cell repertoire in cyclosporine-induced syngeneic graft-versus-host disease: A highly conserved repertoire mediates autoaggression. J Immunol 154:3713, 1995
26. Bernard D, Maurizis JC, Ruse F, Chassagne J, Chollet P, Sauvezie B, De Latour M, Plagne R: Presence of HLA-D/DR antigens on the membrane of breast tumor cells. Clin Exp Immunol 56:215, 1984
27. Natali PG, Giacomini P, Bigotti A: Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 43:660, 1983
28. Parham P: On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 131:2895, 1983
29. Riberdy JM, Newcomb JR, Surman MJ, Balbosa JA, Cresswell P: HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474, 1992
30. Cresswell P: Assembly, transport and function of MHC class II molecules. Annu Rev Immunol 12:259, 1994
31. Carella AM, Gaozza E, Congiu A, Carlier P, Nati S, Truini M, Castellaneta A, Viale M: Cyclosporine-induced graft-vs-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 62:156, 1991
32. Gold DP, Surh CD, Sellins KS, Schroder K, Sprent J, Wilson DB: Rat T cell responses to superantigens. II. Allelic differences in Vβ 8.2 and Vβ 8.5 βchains determine responsiveness to staphylococcal entertoxin B and mouse mammary tumor virus-encoded proteins. J Exp Med 179:63, 1994
33. Lundin KEA, Brinchmann JE, Hansen T: Interactions between staphylococcal superantigens and human T-cell clones are predominantly but not exclusively governed by their T-cell receptor Vβ usage. Scand J lmmunol 39:387, 1994